Update on a Promising New Drug to Treat JM: Vamorolone

Cure JM is making extraordinary progress in juvenile myositis (JM) research, including a partnership with ReveraGen Biotech to advance the drug vamorolone toward a clinical trial in JM.

Vamorolone is a steroid replacement with all the benefits of steroid treatment without devastating side effects. Vamorolone is currently in a clinical trial in Duchenne Muscular Dystrophy children.

Findings so far indicate improved safety relative to prednisone. Cure JM is working with vamorolone’s sponsor, ReveraGen, to design a clinical trial to test the drug’s safety in JM children. ReveraGen’s VP of Research, Eric Hoffmann, Ph.D., gives us an update on vamorolone and the status of a clinical trial in JM.

Family holding a Cure JM sign on a beach

Our Story

Cure JM was founded 19 years ago by a small group of volunteers who wanted to change the world for children with a rare disease few had ever heard of—juvenile myositis, or JM.

Register Now-family-conference-2025

2025 Cure JM Family Conference

We are excited to announce that the Cure JM National Family Conference will be back in 2025! Join us for three days with world-class JM researchers, engaging sessions for all, and social time to connect with new friends. The 15th Annual Cure JM National Family Conference is taking place June 27th -June 29th, 2023, in Chicago, Illinois.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.